Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, February 5, 2001

REFERENCES

• Ayers KM, Clive D, Tucker WE, Jr., Hajian G, de Miranda P. Nonclinical toxicology studies with zidovudine: Genetic toxicity tests and carcinogenicity bioassays in mice and rats. Fundam Appl ToxicoL 1996;32:148–158.
   PubMedGoogle Scholar
• Olivero OA, Anderson LM, Diwan BA, Haines DC, Harbaugh SW, Moskal TJ, Jones AB, Rice JM, Riggs CW, Logsdon D, Yuspa SH, Poirier MC. Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): Tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst. 1997;89:1602–1608.
   PubMed Web of Science ®Google Scholar
• Ayers KM, Torrey CE, Reynolds DJ. A transplacental car-cinogenicity bioassay in CD-1 mice with zidovudine. Fundam Appl ToxicoL 1997;38:195–198.
   PubMedGoogle Scholar
• Reggy AA, Rogers MF, Simonds RJ. Using 3'-azido-2',3'-dideoxythymidine (AZT) to prevent perinatal human im-munodeficiency virus transmission and risk of transpla-cental carcinogenesis. J Natl Cancer Inst. 1997;89:1566–1567.
   PubMed Web of Science ®Google Scholar
• Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173–1180.
   PubMed Web of Science ®Google Scholar
• Hanson IC, Antonelli TA, Sperling RS, Oleske JM, Cooper E, Culnane M, Fowler MG, Kalish LA, Lee SS, McSherry G, Mofenson L, Shapiro DE. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum RetroyiroL 1999;20:463–467.
   PubMedGoogle Scholar
• Toltzis P, Marx CM, Kleinman N, Levine EM, Schmidt EV. Zidovudine-associated embryonic toxicity in mice. J In-fect Dis. 1991;163:1212–1218.
   PubMed Web of Science ®Google Scholar
• Antiretroviral Pregnancy Registry. PharmaResearch Corp., Wilmington, NC. January 1989-July 1997.
   Google Scholar
• Sperling RS, Shapiro DE, McSherry GD, et al. Safety of the maternal-infant zidovudine regimen utilized in the Pe-diatric AIDS Clinical Trials Group 076 Study. AIDS. 1998;12:1805–1813.
   PubMed Web of Science ®Google Scholar
• White A, Eldridge R, Andrews E. Birth outcomes following zidovudine exposure in pregnant women: The Antiretroviral Pregnancy Registry. Acta Paediatr SuppL 1997;421:86–88.
   PubMedGoogle Scholar
• O'Sullivan MJ, Boyer PJ, Scott GB, Parks WP, Weller S, Blum MR, Balsley J, Bryson YJ. The pharmacokinetics and safety of zidovudine in the third trimester of preg-nancy for women infected with human immunodeficiency virus and their infants: Phase I acquired immunodefi-ciency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. Am J Obstet GynecoL 1993;168:1510–1516.
   PubMed Web of Science ®Google Scholar
• Bardeguez AD, Mofenson LM, Spino C, Shapiro DE, Fowler MG, Sperling R, Boyer R. Lack of clinical and immunologic disease progression with transient use of zidovudine (zdv) to reduce perinatal HIV-1 transmission in PACTG 076. In: 12th World Conference on AIDS; Geneva; 1998. ( Abstract 12233).
   Google Scholar
• Culnane M, Fowler M, Lee SS, McSherry G, Brady M, O'Donnell K, Mofenson L, Gortmaker SL, Shapiro DE, Scott G, Jimenez E, Moore EC, Diaz C, Flynn PM, Cunningham B, Oleske J. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. J Am Med Assoc. 1999;281:151–157.
   PubMed Web of Science ®Google Scholar
• Toltzis P, Mourton T, Magnuson T. Comparative embry-onic cytotoxicity of antiretroviral nucleosides. J Infect Dis. 1994;169:1100–1102.
   PubMed Web of Science ®Google Scholar
• Wang Y, Livingston E, Patil S, et al. Pharmacokinetics of didanosine in antepartum and postpartum human immu-nodeficiency virus-infected pregnant women and their neonates: An AIDS Clinical Trials Group study. J Infect Dis. 1999;180:1536–1541.
   PubMed Web of Science ®Google Scholar
• Moodley J, Moodley D, PiIlay K, Coovadia H, Saba J, van Leeuwen R, Goodwin C, Harrigan PR, Moore KH, Stone C, Plumb R, Johnson MA. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodefi-ciency virus type 1-infected pregnant women and their offspring. J Infect Dis. 1998;178:1327–1333.
   PubMed Web of Science ®Google Scholar
• Odinecs A, Nosbisch C, Keller RD, Baughman WL, Unadkat JD. In vivo maternal-fetal pharmacokinetics of stavudine (2',3'-didehydro- 3'-deoxythymidine) in pig-tailed macaques (Macaca nemestrina).Antimicrob Agents Chemother. 1996;40: 196–202.
   PubMed Web of Science ®Google Scholar
• Odinecs A, Pereira C, Nosbisch C, Unadkat JD. Prenatal and postpartum pharmacokinetics of stavudine (2',3'-didehydro- 3'-deoxythymidine) and didanosine (dideoxyinosine) in pigtailed macaques (Macaca nemestrina). Antimicrob Agents Chemother. 1996;40:2423–2425.
   PubMed Web of Science ®Google Scholar
• Sandberg JA, Binienda Z, Lipe G, Rose LM, Parker WB, Ali SF, Slikker W, Jr. Placental transfer and fetal disposition of 2',3'-dideoxycytidine and 2',3'-dideoxyinosine in the rhesus monkey. Drug Metab Dispos. 1995;23:881–884.
   PubMed Web of Science ®Google Scholar
• Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS. 1998;12:1735–1744.
   PubMed Web of Science ®Google Scholar
• Mofenson, L. Perinatal exposure to zidovudine: Benefits and risks. N Engl J Med. 2000;343:803–805.
   PubMed Web of Science ®Google Scholar
• Boxwell DE, Styrt BA. Lactic acidosis (LA) in patients receiving nucleoside reverse transcriptase inhibitors (NRTIs). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA; Septem-ber 26–29, 1999. ( Abstract 1284).
   Google Scholar
• Lbdah JA, et al. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med. 1999;340:1723–1731.
   PubMed Web of Science ®Google Scholar
• Strauss AW, Bennett MJ, Rinaldo P, et al. Inherited long-chain 3-hydroxyacyl-00A dehydrogenase deficiency and a fetal-maternal interaction cause maternal liver disease and other pregnancy complications. Semin PerinatoL 1999;23:100–112.
   PubMed Web of Science ®Google Scholar
• Sims HF, Brackett JC, Powell CK, et al. The molecular basis of pediatric long-chain 3-hydroxyacyl Co-A dehy-drogenase deficiency associated with maternal acute fatty liver of pregnancy. Proc Natl Acad Sci USA. 1995;92:841–845.
   PubMed Web of Science ®Google Scholar
• Lbdah JA, Yang Z, Bennett MJ. Minireview: Liver disease in pregnancy and fetal fatty acid oxidation defects. Mol Genetics Metab. 2000;71:182–189.
   PubMed Web of Science ®Google Scholar
• Grimbert S, Fromenty B, Fisch C, et al. Decreased mito-chondrial oxidation of fatty acids in pregnant mice: Pos-sible relevance to development of acute fatty liver of pregnancy. Hepatology. 1993;17:628–637.
   PubMed Web of Science ®Google Scholar
• Grimbert S, Fisch C, Deschamps D, et al. Effects of fe-male sex hormones on mitochondria: Possible role of acute fatty liver of pregnancy. Am J Physiol. 1995;268:6107.
   Google Scholar
• Fortgang IS, et al. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analogue antiretroviral therapy. Am J GastroenteroL 1995;90:1433–1436.
   PubMed Web of Science ®Google Scholar
• Gerard Y, Maulin L, Yazdanpanah Y, et al. Symptomatic hyperlactatemia: An emerging complication of antiretroviral therapy. AIDS. 2000;14:2723–2730.
   PubMed Web of Science ®Google Scholar
• Luzzati R, Del Bravo P, Di Perri G, Luzzani A, Concia E. Riboflavine and severe lactic acidosis. Lancet. 1999;353:901–902.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company. Healthcare Provider Im-portant Drug Warning Letter. January 5, 2001.
   Google Scholar
• The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: Absence of clear evidence for mito-chondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr. 2000;15:261–268.
   Google Scholar
• Jackson JB, Becker-Pergola G, Guay L, et al. Identifica-tion of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmis-sion. AIDS. 2000;14:F111–F115.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Easley KA, Dray EJ, et al. Absence of car-diac toxicity of zidovudine in infants. N Engl J Med. 2000;343:759.
   PubMed Web of Science ®Google Scholar
• Sullivan J, Cunningham C, Dorenbaum A, et al. Genotypic resistance analysis in women participating in PACTG 316 with HIV-1 RNA10,000 copies/ml. XIII InternationalAIDS Conference; Durban, South Africa; July 9–14, 2000. ( Abstract LbOr 14).
   Google Scholar
• Mirochnick M, Fenton T, Gagnier P, Pay J, Gwynne M, Siminski S, Sperling RS, Beckerman K, Jimenez E, Yogev R, Spector SA, Sullivan JL. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-in-fected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis. 1998;178:368–374.
   PubMed Web of Science ®Google Scholar
• Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabüto C, Sherman J, Bakaki P, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F, Jackson JB. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795–802.
   PubMed Web of Science ®Google Scholar
• Jackson JB, Mracnz M, Guay L, et al. Selection of nevirapine (NVP) resistance mutations in Ugandan women and infants receiving NVP prophylaxis to prevent HIV-1 vertical trans-mission (HIVNET 012). XIII International AIDS Conference; Durban, South Africa; July 9–14, 2000. ( Abstract LbOr 13).
   Google Scholar
• Food and Drug Adminstration Advisory. FDA Public Health Advisory: Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for treatment of human immu-nodeficiency virus (HIV). Food and Drug Administration, Public Health Service, Department of Health and Human Services, Rockville, MD: June 11,1997.
   Google Scholar
• Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med. 1997;127:947.
   PubMed Web of Science ®Google Scholar
• Eastone JA, Decker CF. New-onset diabetes mellitus asso-ciated with use of protease inhibitor. Ann Intern Med. 1997;127:948.
   PubMed Web of Science ®Google Scholar
• Dube M. Metabolic complications of antiretroviral therapies. AIDS Clinical Care. 1998;10:41–48.
   PubMedGoogle Scholar
• Lorenzi P, Spicher VM, Laubereau B, Hirschel B, Kind C, Rudin C, Irion O, Kaiser L. Antiretroviral therapies in preg-nancy: Maternal, fetal and neonatal effects. Swiss HIV Co-hort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS. 1998;12:F241–247.
   PubMed Web of Science ®Google Scholar
• Martin R, Boyer P, Hammill H, Peavy H, Platzker A, Settlage R, Shah A, Sperling R, Tuomala R, Wu M. Incidence of premature birth and neonatal respiratory disease in infants of HIV-positive mothers. The Pediatric Pulmonary and Car-diovascular Complications of Vertically Transmitted Human Immunodeficiency Virus Infection Study Group. J Pediatr. 1997;131:851–856.
   PubMed Web of Science ®Google Scholar
• Leroy V, Ladner J, Nyiraziraje M, De Clercq A, Bazubagira A, Van de Perre P, Karita E, Dabis F. Effect of HIV-1 infection on pregnancy outcome in women in Kigali, Rwanda, 1992-1994. Pregnancy and HIV Study Group. AIDS. 1998;12:643–650.
   PubMed Web of Science ®Google Scholar
• Brocklehurst P, French R. The association between mater-nal HIV infection and perinatal outcome: A systematic review of the literature and meta-analysis. Br J Obstet GynaecoL 1998;105:836–848.
   PubMedGoogle Scholar
• Wara D, Tuomala R, Bryson Y, et al. PACTG 358- safety, pharmacokinetics and antiretroviral activitiy of indinavir, zidovudine (ZDV), and lamivudine (3TC) in HIV-1 seroposi-tive pregnant women and infants. 2nd Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants; Montreal, Canada; September 1–6, 1999. ( Abstract 447).
   Google Scholar
• Hayashi S, Beckerman K, Homma M, Kosel BW, Aweeka FT. Pharmacokinetics of indinavir in HIV-positive pregnant women. AIDS. 2000;14:1061–1062.
   PubMed Web of Science ®Google Scholar
• Casey BM, Bawdon RE. Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. Am J Obstet Gynecol. 1998;179:758–761.
   PubMed Web of Science ®Google Scholar
• Chaube S, Murphy ML. The effects of hydroxyurea and related compounds on the rat fetus. Cancer Res. 1966;26:1448–1457.
   PubMed Web of Science ®Google Scholar
• Ferm V. Severe developmental malformations. Arch PathoL 1966;81:174–177.
   Google Scholar
• Khera K. A teratogenicity study on hydroxyurea and diphe-nylhydantoin in cats. Teratology. 1979;20:447–452.
   PubMedGoogle Scholar
• Wilson JG, Scott WJ, Ritter EJ, Fradkin R. Comparative distribution and embryotoxicity of hydroxyurea in pregnant rats and rhesus monkeys. Teratology. 1975;11:169–178.
   PubMedGoogle Scholar
• Aliverti V, Bonanomi L, Giavini E. Hydroxyurea as a reference standard in teratological screening. Comparison of the embryotoxic and teratogenic effects following single intrap-eritoneal or repeated oral administrations to pregnant rats. Arch Toxicol SuppL 1980;4:239–247.
   PubMedGoogle Scholar
• DeSesso JM, Jordan RL. Drug-induced limb dysplasias in fetal rabbits. Teratology. 1977;15:199–211.
   PubMedGoogle Scholar
• Fritz H, Hess R. Effects of hydroxyurea on postnatal growth and behaviour of rats. Agents Actions. 1980;10:389–393.
   PubMedGoogle Scholar
• Sylvester RK, Lobell M, Teresi ME, Brundage D, Dubowy R. Excretion of hydroxyurea into milk. Cancer Res. 1987;60:2177–2178.
   Google Scholar
• Diav-Citrin O, Hunnisett L, Sher GD, Koren G. Hydroxyurea use during pregnancy: A case report in sickle cell disease and review of the literature. Am J HematoL 1999;60:148–150.
   PubMed Web of Science ®Google Scholar